World journal of clinical oncology最新文献

{"title":"Exploring a new chapter in traditional Chinese medicine: The potential of <i>Calculus bovis</i> in liver cancer treatment.","authors":"Huang Du, Hong-Bin Chen, Yu Zhao","doi":"10.5306/wjco.v15.i12.1520","DOIUrl":"10.5306/wjco.v15.i12.1520","url":null,"abstract":"<p><p>In the ongoing quest for new treatments in medicine, traditional Chinese medicine offers unique insights and potential. Recently, studies on the ability of <i>Calculus bovis</i> to inhibit M2-type tumour-associated macrophage polarisation by modulating the Wnt/β-catenin signalling pathway to suppress liver cancer have undoubtedly revealed new benefits and hope for this field of research. The purpose of this article is to comment on this study and explore its strengths and weaknesses, thereby providing ideas for the future treatment of liver cancer.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1520-1527"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DEK::AFF2 fusion-associated middle ear non-keratinizing squamous cell carcinoma: A case report.","authors":"Yi-Wen Sun, Ying Zhou, Xiao-Yang Liu, Dan-Hua Shen","doi":"10.5306/wjco.v15.i12.1501","DOIUrl":"10.5306/wjco.v15.i12.1501","url":null,"abstract":"<p><strong>Background: </strong>Primary squamous cell carcinoma (SCC) of the middle ear is rare, with non-keratinizing basaloid types being exceptionally uncommon. Distinguishing these cancers, often caused by viral factors (<i>e.g.</i>, human papillomavirus or Epstein-Barr virus), or specific genetic alterations (<i>e.g.</i>, bromodomain-containing protein 4-nuclear protein in <i>testis fusion gene</i> or <i>Ewing sarcoma breakpoint region 1</i> gene fused with FLI chromosomal rearrangement), from other cranial conditions, is difficult. The recently identified DEK::AFF2 non-keratinizing SCC (NKSCC) is a novel subtype, fitting the World Health Organization classification of head and neck neoplasms. Less than 30 cases have been reported, highlighting the need for further studies.</p><p><strong>Case summary: </strong>A 55-year-old female patient first exhibited signs of illness over 10 years ago with persistent discomfort in the left external auditory canal, accompanied by skin irritation and bleeding. One month prior to seeking professional help, she experienced hearing loss and a sensation of obstruction in the affected ear, intermittently accompanied by ringing sounds, but no dizziness. An unusual mass was detected in the left auditory canal, confirmed through biopsy as moderately differentiated epithelial squamous cancer cells. This led to her admission to our hospital, where the final diagnosis confirmed as \"NKSCC linked to a positive DEK::AFF2 fusion\". The patient underwent surgical excision, followed by three cycles of local radiation therapy. Yet, metastasis to the lumbar vertebrae occurred 19 months post-treatment, followed by neck lymph node swelling detected three months after a physical examination. The patient died nine months later despite surgical removal of the metastatic lesion.</p><p><strong>Conclusion: </strong><i>DEK::AFF2</i> gene fusion-associated NKSCC of the middle ear carries a grim prognosis and presents an emerging challenge.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1501-1506"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study.","authors":"Morena Fasano, Mario Pirozzi, Pasquale Vitale, Vincenzo Damiano, Graziana Ronzino, Stefano Farese, Vincenzo Carfora, Giuseppina Ciccarelli, Ilaria Di Giovanni, Sergio Facchini, Gregorio Cennamo, Michele Caraglia, Fortunato Ciardiello, Raffaele Addeo","doi":"10.5306/wjco.v15.i12.1468","DOIUrl":"10.5306/wjco.v15.i12.1468","url":null,"abstract":"<p><strong>Background: </strong>Squamous cell carcinoma of the head and neck (SCCHN) accounts for 3% of all malignant tumors in Italy. Immune checkpoint inhibitors combined with chemotherapy is first-line treatment for SCCHN; however, second-line treatment options are limited. Taxanes are widely used for combination therapy of SCCHN, as clinical trials have shown their efficacy in patients with this disease, particularly in patients with prior therapy.</p><p><strong>Aim: </strong>To perform a multicenter retrospective study on the efficacy and safety of weekly paclitaxel for SCCHN.</p><p><strong>Methods: </strong>All patients were previously treated with at least one systemic therapy regimen, which included platinum-based therapy in the vast majority. No patient received prior immunotherapy.</p><p><strong>Results: </strong>Median progression-free survival (mPFS) was 3.4 months and median overall survival (mOS) was 6.5 months. Subgroup analysis was performed according to three principal prognostic factors: Smoking, alcohol consumption, and body mass index. Analysis demonstrated reduced survival, both mOS and mPFS, in the unfavorable prognostic groups, with the biggest deltas observed in mOS.</p><p><strong>Conclusion: </strong>Weekly paclitaxel provided favorable survival and disease control rates, with low severe adverse events. Paclitaxel is a safe and valid therapeutic option for patients with SCCHN who received prior therapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1468-1480"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic pancreatitis as a driving factor for pancreatic cancer: An epidemiological understanding.","authors":"Amlan Das, Akash Bararia, Sanghamitra Mukherjee, Nilabja Sikdar","doi":"10.5306/wjco.v15.i12.1459","DOIUrl":"10.5306/wjco.v15.i12.1459","url":null,"abstract":"<p><p>The retrospective study by Lew <i>et al</i> (2022) examined the rising hospitalization rates for chronic pancreatitis (CP) and its association with pancreatic ductal adenocarcinoma (PDAC), revealing significant ethno-racial disparities and risk factors. Overweight black men aged 40-59 years and white men over 40 years with higher incomes showed an elevated risk of PDAC among CP patients. The study, which included 14.2 million admissions from 2016-2017, found that 2.6% of adult patients were diagnosed with CP, with white males being the majority. Multivariate regression analysis identified men, black individuals, those aged 40-59 years, and individuals with a body mass index (BMI) between 25 and 29.9 as having an increased risk for CP. Moreover, 0.78% of CP patients also had PDAC, with older age and BMI being significant risk factors for developing PDAC in CP patients. The study also highlighted disparities in healthcare access and utilization among different socioeconomic and ethno-racial groups, which may impact the risk and outcomes of CP and PDAC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1459-1462"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orbital and sinus rhabdomyosarcoma with concurrent central retinal artery occlusion: A case report.","authors":"Yu Ma, Bo Jia, Xiao-Juan He, Yue-Xia Cai, Jin-Ying Chen, Jing-Xiang Zhong","doi":"10.5306/wjco.v15.i12.1507","DOIUrl":"10.5306/wjco.v15.i12.1507","url":null,"abstract":"<p><strong>Background: </strong>Both rhabdomyosarcoma (RMS) and central retinal artery occlusion (CRAO) are rare medical diseases, and their simultaneous occurrence in the same patient is extraordinarily uncommon. This study presents a comprehensive overview of the clinical manifestations, diagnostic imaging results, and therapeutic interventions of a patient with both conditions.</p><p><strong>Case summary: </strong>In this report, we present a 30-year-old male who presented with significant protrusion, pain and vision loss and was diagnosed with RMS in the orbit and sinus with CRAO. Following resection of the sinus and orbital mass and enucleation of the right eye, the patient experienced symptom improvement.</p><p><strong>Conclusion: </strong>This article provides an in-depth analysis of the patient's clinical manifestations, the tumor's anatomical origin, and the etiology of CRAO. The concurrent manifestation of both RMS and CRAO is exceedingly uncommon in clinical practice.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1507-1513"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetic ulcer with cutaneous squamous cell carcinoma: A case report.","authors":"Yun Luo, Chen-Ying Li, Yu-Qing Wang, Sheng-Min Xiang, Cheng Zhao","doi":"10.5306/wjco.v15.i12.1514","DOIUrl":"10.5306/wjco.v15.i12.1514","url":null,"abstract":"<p><strong>Background: </strong>Chronic skin ulcers are a risk factor for the development of skin tumors. In patients with diabetes, chronic refractory ulcers may also contribute to higher susceptibility to skin tumors. Timely surgical removal of chronic and nonhealing diabetic foot ulcers can effectively prevent progression to squamous cell carcinoma. Such cases may be misdiagnosed owing to currently insufficient clinical evidence. However, in cases of chronic ulcer wounds, it is crucial to enhance clinical awareness regarding their potential progression into malignant lesions.</p><p><strong>Case summary: </strong>An 84-year-old male patient with diabetes presented with a significantly ulcerated area on his foot. The ulcer had been present to varying degrees since 1996. Between 2012 and July 2019, even after receiving treatments such as herbal medicines or heat clearance and detoxification complete healing of the wound was not achieved. In July 2020, histopathological analysis confirmed a well-differentiated cutaneous squamous cell carcinoma. After the treatments, the ulcer wound healed slowly and did not expand.</p><p><strong>Conclusion: </strong>Potentially malignant lesions in chronic ulcer wounds should be identified and treated in a timely manner to prevent their progression.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1514-1519"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline pathogenic variants among high hereditary risk patients with breast and ovarian cancer and unaffected subjects in Lebanese Arab women.","authors":"Hiba A Moukadem, Mohammad A Fakhreddine, Nada Assaf, Nadine Safi, Ahmad Al Masry, Monita Al Darazi, Rami Mahfouz, Nagi S El Saghir","doi":"10.5306/wjco.v15.i12.1481","DOIUrl":"10.5306/wjco.v15.i12.1481","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of germline pathogenic variants in high hereditary risk breast and/or ovarian cancer patients and unaffected subjects referred for testing is an unmet need in low and middle-income countries.</p><p><strong>Aim: </strong>To determine the prevalence of germline pathogenic variants in high hereditary risk patients with breast and/or ovarian cancer and unaffected individuals.</p><p><strong>Methods: </strong>We retrospectively reviewed records of patients and unaffected subjects referred for germline pathogenic variant testing due to high hereditary risk between 2010-2020. Data was collected and analyzed on Excel sheet.</p><p><strong>Results: </strong>In total, 358 individuals were included, including 257 patients and 101 unaffected individuals with relatives with breast or ovarian cancer. The prevalence of <i>breast cancer susceptibility gene (BRCA) 1/2</i> pathogenic variants was 8.63% (19/220) in patients with breast cancer, and 15.1% (5/33) in those with ovarian cancer. Among the 25 of 220 patients with breast cancer tested by next-generation sequencing, 3 patients had pathogenic variants other than <i>BRCA1/2</i>. The highest risk was observed in those aged 40 years with breast cancer and a positive family history, where the <i>BRCA1/2</i> prevalence was 20.1% (9/43). Among the unaffected subjects, 31.1% (14/45) had the same <i>BRCA1/2</i> pathogenic variants in their corresponding relatives. Among the subjects referred because of a positive family history of cancer without known hereditary factors, 5.35% (3/56) had pathogenic variants of <i>BRCA1</i> and <i>BRCA2</i>. The c.131G>T nucleotide change was noted in one patient and two unrelated unaffected subjects with a <i>BRCA1</i> pathogenic variant.</p><p><strong>Conclusion: </strong>This study showed a 8.63% prevalence of pathogenic variants in patients with breast cancer and a 15.1% prevalence in patients with ovarian cancer. Among the relatives of patients with <i>BRCA1/2</i> pathogenic variants, 31% tested positive for the same variant, while 5.3% of subjects who tested positive due to a family history of breast cancer had a <i>BRCA</i> pathogenic variant.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1481-1490"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New cheaper human papilloma virus mass screening strategy reduces cervical cancer incidence in Changsha city: A clinical trial.","authors":"Yue-E Zu, Si-Feng Wang, Xing-Xing Peng, Yong-Chun Wen, Xue-Xiang Shen, Xiao-Lan Wang, Wen-Bo Liao, Ding Jia, Ji-Yang Liu, Xiang-Wen Peng","doi":"10.5306/wjco.v15.i12.1491","DOIUrl":"10.5306/wjco.v15.i12.1491","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is the second leading cause of death in women worldwide, second only to breast cancer. Around 80% of women have been infected with human papillomavirus (HPV) in their lifetime. Early screening and treatment are effective means of preventing cervical cancer, but due to economic reasons, many parts of the world do not have free screening programs to protect women's health.</p><p><strong>Aim: </strong>To increase HPV cervical cancer screening in Changsha and reduce the incidence of cervical cancer.</p><p><strong>Methods: </strong>Cervical cancer screening included gynecological examination, vaginal secretion examination and HPV high-risk typing testing. Cervical cytology examination (ThinPrep cytology test) was performed for individuals who test positive for HPV types other than 16 and 18. Vaginal colposcopy examination was performed for HPV16 and 18 positive individuals, as well as for those who were positive for ThinPrep cytology test. If the results of vaginal colposcopy examination were abnormal, histopathological examination was performed. We conducted a cost-benefit analysis after 4 years.</p><p><strong>Results: </strong>From 2019 to 2022, 523437 women aged 35-64 years in Changsha city were screened and 73313 were positive, with a 14% positive rate. The detection rate of precancerous lesions of cervical cancer was 0.6% and the detection rate of cervical cancer was 0.037%. Among 311212 patients who underwent two cancers examinations, the incidence rate was reduced by more than half in the second examination. The average screening cost per woman was 120 RMB. The average cost of detecting early cases was 10619 RMB, with an early detection cost coefficient of 0.083.</p><p><strong>Conclusion: </strong>Our screening strategy was effective and cost-effective, making it valuable for early diagnosis and treatment of cervical cancer. It is worth promoting in economically limited areas.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1491-1500"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements and challenges in the treatment of esophageal cancer: A comprehensive review.","authors":"Grigorios Christodoulidis, Sara Eirini Agko, Konstantinos Eleftherios Koumarelas, Marina Nektaria Kouliou, Dimitris Zacharoulis","doi":"10.5306/wjco.v15.i12.1463","DOIUrl":"10.5306/wjco.v15.i12.1463","url":null,"abstract":"<p><p>Esophageal cancer (EC) is an aggressive malignancy with a poor prognosis, ranking seventh in incidence and sixth cancer-related deaths globally. EC is classified in two main types, the esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), with ESCC being more common in Eastern Europe, South Asia, and Africa, while EAC is prevalent in Western Europe and North America. Molecular analysis identifies three subgroups of ESCC, each with distinct genetic mutations and treatment responses. Early-stage EC is often difficult to detect, leading to late-stage diagnoses that necessitate systemic drug therapies, including molecular-targeted therapies and immunotherapies. Immunotherapy, particularly immune checkpoint inhibitor, has shown promising results in improving survival rates for metastatic or persistent EC. It is particularly important to target to multidisciplinary combination therapies, integrating surgery, chemoradiotherapy, targeted therapy and immunotherapy. Additionally, radioimmunotherapy is being explored for its potential to enhance treatment efficacy, especially in advanced and metastatic tumors. However, the pathological complete response rate to neoadjuvant chemoradiotherapy remains suboptimal, highlighting the need for novel treatment strategies. Future research should focus on optimizing treatment combinations and identifying predictive biomarkers to improve clinical outcomes for EC patients.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 12","pages":"1463-1467"},"PeriodicalIF":2.6,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole exome sequencing identifies risk variants associated with intracranial epidermoid cyst deterioration: A case report.","authors":"Zhao-Na Song, Yan Cheng, Dan-Dan Wang, Ming-Jun Li, Xiang-Rong Zhao, Fa-Wang Li, Zhen Liu, Xiao-Ru Zhu, Xiao-Dong Jia, Yu-Fang Wang, Feng-Fan Liang","doi":"10.5306/wjco.v15.i11.1428","DOIUrl":"10.5306/wjco.v15.i11.1428","url":null,"abstract":"<p><strong>Background: </strong>Intracranial epidermoid cyst (IEC) transformation to malignant squamous cell carcinoma (SCC) is extremely rare, and its etiology is yet unknown. Currently, SCC is treated by performing surgery, followed by a combination of radiotherapy and chemotherapy. It is crucial to identify efficient and trustworthy therapeutic targets for SCC to improve its diagnosis, prognosis, and treatment.</p><p><strong>Case summary: </strong>In this study, we report the case of a 47-year-old female patient with SCC, which progressed from IEC in the left internal capsule region. The patient was sought treatment at our hospital for severe diplopic vision, accompanied with speech disorder and memory loss. Based on the clinical and postoperative pathology, this patient was finally diagnosed with SCC. To identify disease-causing variants, whole exome sequencing (WES) was performed on the proband. WES revealed two pathogenic missense mutations on Gap junction protein beta 2 (GJB2) (c.257C>T) and Toll-like receptor 2 (TLR2) (c.1039A>G), respectively.</p><p><strong>Conclusion: </strong>This study provided the first clinical evidence for demonstrating the role of GJB2 and TLR2 in IEC development and treatment. We further confirmed WES as a robust and reliable technique for underlying rare and complex disease-related genetic factor identification.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1428-1434"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}